Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
• 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday, TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events:
再生元制药公司（NASDAQ: REGN）宣布以下2024年9月投资者活动：
Investor Conference Presentations
投资者会议演示文稿
• Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on
Wednesday, September 4, 2024
摩根士丹利第22届全球医疗保健大会，美国东部时间上午11:30
2024年9月4日星期三
• 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday,
September 5, 2024
2024年富国医疗健康大会，美国东部时间星期四下午12:45
2024年9月5日
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
可以从Regeneron网站的“投资者与媒体”页面访问这些会议。该网站将在至少30天内归档网络广播的播放记录和文字记录。
Oncology Webcast Information
肿瘤学网络研讨信息
• European Society for Medical Oncology (ESMO) 2024 conference call and webcast at 14:30 CEST/8:30 AM EDT on Monday, September 16, 2024
欧洲医学肿瘤学协会（ESMO）2024年电话会议和网络研讨会，美国东部时间上午8:30/中欧夏令时下午2:30，于2024年9月16日星期一举行
Regeneron will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio. A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at . To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
Regeneron将主持电话会议和同时进行的网络广播，以分享公司的肿瘤学投资组合的最新进展情况。您可从Regeneron网站的“投资者与媒体”页面访问该网络广播链接。若要通过电话参加，请在此链接上提前注册。注册后，所有电话参与者将收到一封确认电子邮件，并详细说明如何加入电话会议，包括拨入号码以及可用于访问电话会议的唯一密码和注册ID。公司将在至少30天内归档电话会议和网络广播的重播。
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
关于瑞利康
再生元制药公司是一家领先的生物技术公司，专注于为患有严重疾病的人发明、开发和商业化变革性药物。我们由医学科学家创立并领导，独特的科学转化医学的能力使我们在实验室里研究开发出许多获批的治疗方案和正在研发的药物候选项。我们的药物和管线旨在帮助患者治疗眼部疾病、过敏和炎症性疾病、癌症、心血管和代谢性疾病、神经系统疾病、血液病、传染病和罕见病。
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
再生元利用其专有技术（如VelociSuite，能够生产优化的全人类抗体和新的双特异性抗体）推动科学发现的边界并加速药物研发。我们正在通过来自再生元遗传学中心和开创性的遗传学医学平台的数据驱动见解，塑造医学的下一个领域，使我们能够识别创新目标和互补方法来潜在地治疗或治愈疾病。
For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X.
欲了解更多信息，请访问 或关注LinkedIn、Instagram、Facebook或X上的再生元。
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
联系方式：
投资者关系
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Source: Regeneron Pharmaceuticals, Inc.
消息来源：再生元制药公司。
